Sign Out
[Applicable to 2.5 mg - Only]: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
[Applicable to 2.5 mg and 5 mg]: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy under Precautions).
Continue with Google